Regeneron Pharmaceuticals Inc
REGNHealthcare|Biotechnology|USA
$763.04
+1.19 (+0.16%)
DCF (FCF)
$641.30
Tangible Book
$283.77
Graham Number
$532.32
Earnings Power
$496.16
Upcoming Data Readouts (96)
Jul 2026
Est. completion
P2B-cell Non-Hodgkin Lymphoma (B-NHL)
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03888105n=515
Jul 2026
Est. completion
P1Healthy Volunteer
Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults
NCT06669234n=56
Aug 2026
Est. completion
P2Chronic Rhinosinusitis Without Nasal Polyps
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
NCT06691113n=60
Aug 2026
Est. completion
P4Diabetic Macular Edema (DME)
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
NCT06662994n=15
Aug 2026
Est. completion
P1P2Advanced Solid Tumors
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
NCT04626635n=933
Sep 2026
Est. completion
P4Eosinophilic Esophagitis (EoE)
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
NCT06665971n=30
Sep 2026
Est. completion
Prurigo Nodularis
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
NCT05991323n=100
Oct 2026
Est. completion
P3Atopic Dermatitis
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
NCT02612454n=880
Nov 2026
Est. completion
Nov 2026
Est. completion
P2Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
NCT07431086n=120
Dec 2026
Est. completion
P3Chronic Obstructive Pulmonary Disease
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
NCT06208306n=700
Dec 2026
Est. completion
P2Carcinoma, Non-Small-Cell Lung
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
NCT06623656n=112
Dec 2026
Est. completion
Dec 2026
Est. completion
P1Healthy Volunteers With Hyperlipidemia
A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults
NCT06452771n=59
Dec 2026
Est. completion
P2Asthma
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
NCT05347771n=240
Dec 2026
Est. completion
P4Asthma
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
NCT06572228n=250
Jan 2027
Est. completion
Jan 2027
Est. completion
P1Advanced Solid Tumor
A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab
NCT05259709n=50
Jan 2027
Est. completion
P3Chronic Rhinosinusitis With Nasal Polyps
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360n=210
Jan 2027
Est. completion
P3Chronic Rhinosinusitis With Nasal Polyps
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347n=210
Awaiting Results (17)
Trials past primary completion date but still active — data readout may be imminent.
Jul 2026
Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)
NCT04550962Jun 2026
P2
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
NCT06299111May 2026
P1
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
NCT02651662May 2026
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
NCT05568459Apr 2026
P2
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441Apr 2026
Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
NCT06099704Feb 2026
P2
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
NCT05831176Jan 2026
P1
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
NCT05704634